Learn, Analyse & Invest
only with
only with
+91
Download Orca
Bacil Pharma Ltd.
Bacil Pharma
Bacil Pharma Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Small-cap - With a market cap of ₹30.28 Cr.
| EX-Date | Purpose |
|---|---|
| 30 06 2021 | Audited Results & Quarterly Results |
| 14 08 2021 | Quarterly Results |
| 12 11 2021 | Quarterly Results |
| 14 02 2022 | Quarterly Results |
| 30 05 2022 | Audited Results |
| 12 08 2022 | Quarterly Results |
| 02 11 2022 | Quarterly Results |
| 11 02 2023 | Quarterly Results |
| 16 05 2023 | Audited Results |
| 14 08 2023 | Quarterly Results |
| 10 11 2023 | Quarterly Results |
| 13 02 2024 | Quarterly Results |
| 27 09 2024 | Increase in Authorised Capital |
| 15 10 2024 | Inter alia, to discuss, consider and approve agendas as follows: - 1. To discuss and take final decision on acquisition of equity shares of M/s CNX Corporation Limited (CCL), from the existing shareholders of CCL, on which the Board of Directors has given their initial approval in its meeting held on 27th September 2024, the board will decide the no. of shares to be acquire, price of acquisition, mode of payment consideration etc. and other terms and conditions for acquisition of Eq. Shares of CCL subject to the due diligence and valuation reports in its meeting. 2. To discuss and approve the proposal for offer, Issue, and allot Equity Shares of the company on a Preferential Basis to the shareholders of M/s CNX Corporation Limited (CCL) for consideration other than cash (share swap), which will be determined in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (SEBI ICDR Regulations), for a consideration other than cash (share swap)(for discharge of entire purchase consideration) to the shareholders of M/s CNX Corporation Limited (CCL), on such terms and conditions which will be approved by board in this meeting, subject to the shareholders approval in ensuing general meeting of the company. 3. To discuss and approve the proposal for fund raising by offer, Issue, and allot Equity Shares |
| 23 10 2024 | Quarterly Results |
| 21 01 2025 | Quarterly Results |
| 26 05 2025 | Audited Results |
| 16 07 2025 | Inter alia, to consider and approve:- 1. To consider and discuss the appointment of a new Executive Director and Chief Financial Officer (CFO) of the Company; 2. To consider and discuss the resignation of the present Chief Financial Officer (CFO) of the Company. 3. Any other business with the permission of chair. |
| 12 08 2025 | Quarterly Results |
| 25 08 2025 | Inter alia, to consider and approve:- 1. Discussion on Appointment of M/s Sarang Shivajirao Chavan& Associate as a Statutory Auditor of the Company; 2. Discussion on Appointment of New Director. 3. Any other business with the permission of Chairperson. |
| 05 09 2025 | Inter alia, To discuss and approve the following matters: ? Discussion on Notice for 38th Annual General Meeting for the Company. ? Discussion on Director Report of the Company for the Financial Year 2024-2025. ? Discussion to Fix Date, Place and Timing of 38th Annual General Meeting of the Company ? Discussion on matter related to Loan to Equity shares of the Company. ? Any other business with the permission of Chairperson. |
| 13 11 2025 | Quarterly Results |
| 13 02 2026 | Quarterly Results |
| 22 05 2026 | Audited Results |
| 26 06 2026 | Inter alia, to consider and evaluate proposals for raising funds by the Company through one or more permissible modes, subject to such statutory and regulatory approvals as may be required, including but not limited to: 1.. Preferential Issue (including preferential allotment of equity shares and/or convertible securities); 2. Rights Issue; Any other permissible mode or combination thereof, as may be considered appropriate by the Board, in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws. The Board may also consider and transit any other business, if any, which may be placed before the Board with the permission of the Chairman |
| 09 07 2026 | Inter alia, to consider and approve the following:- 1. The proposal for raising funds by way of a Rights Issue of equity shares to the eligible equity shareholders of the Company for an aggregate amount of up to Rs.50,00,00,000 (Rupees Fifty Crores Only), in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable laws, subject to such statutory and regulatory approvals as may be required. 2. The proposal for increase in the Authorised Share Capital of the Company, if required, to facilitate the proposed Rights Issue and to ensure adequate headroom for issuance of equity shares pursuant thereto. 3. Consequent alteration of the Capital Clause of the Memorandum of Association of the Company and other related documents, if required, subject to the approval of the Board and the shareholders of the Company, as applicable. 4. To determine and approve the detailed terms and conditions of the Rights Issue, including but not limited to the issue size, rights entitlement ratio, issue price, record date, rights issue schedule, appointment of intermediaries, draft Letter of Offer and such other matters incidental or connected therewith. 5. Discussion on Appointment and Resignation of Directors. 6. Any other matter incidental or connected with the proposed Rights Issue and increase in the Authorised Share Capital |
| 12 08 2026 | Quarterly Results |
| 25 08 2026 | Inter alia, to consider and approve Appointment of Directors |
| 29 08 2026 | A.G.M. & Inter alia, to consider and approve:- 1. Discussion on Notice for 39th Annual General Meeting for the Company. 2. Discussion on Approval of Director Report of the Company for the Financial Year 2025-2026. 3. Discussion to Fix Date, Place and Timing of 39th Annual General Meeting of the Company 4. Any other business with the permission of Chairperson. |